chemotherapy to the majority of patients. Unfortunately, previous studies have not revealed clinical features that might predict the response to 5-FU leading some workers to investigate the biochemical characteristics of individual tumours; in particular the enzymes considered responsible for the metabolism of the drug (Moran & Heidelberger, 1979) .
In its original form 5-FU is inactive and, in order to exert its cytotoxic effect, has to be converted to one of its active nucleotides down one of several metabolic pathways. In the first of these, long considered the most important 5-FU is converted to 5-fluorodeoxyuridine 5 '-monophosphate (FdUMP) . This nucleotide is a potent inhibitor of thymidylate synthetase and, by interfering with the supply of thymidine triphosphate, affects the synthesis of DNA. More recently it has been suggested that not all the cytotoxic action of 5-FU can be explained in this way and that a further important effect is incorporation of 5-FU into RNA (Heidelberger et al., 1983) . Such an action requires conversion of 5-FU to 5-fluorouridine 5'-monophosphate (FUMP) either directly using the enzyme phosphoribosyl transferase (PRT) or indirectly via 5-fluorouridine, using the enzymes uridine phosphorylase (UP) and uridine kinase (UK).
There is, as yet, little data on the levels of these three enzymes in human colorectal epithelium. For this reason and because of their obvious importance in the initial steps of metabolism of 5-FU this study was designed to measure the levels of enzymes in a series of matched normal and malignant specimens of human colorectal tissue.
Twenty-eight patients presenting with primary malignant lesions of the colorectum were studied (males = 17, females =1 with a mean age of 67.3 range 51-82). Details of the site, stage and grade of individual tumours are contained in Table I . The assay of phosphoribosyl transferase (PRT) (EC 2.4.2.9) was adapted from the radioisotopic method described by Reyes (1969) . Sixty ,ul of extract (1OmM tris/HCl, pH7.5) was incubated at 37°C for 30min with 20u1 of 6.0mM [6-3H] Despite the controversy that continues to surround the mechanism of cytotoxicity of 5-FU, be it inhibition of DNA synthesis or a direct effect on the maturation of RNA (Heidelberger et al., 1983) , it is clear that to have any effect 5-FU must be converted to one of two active nucleotides, FdUMP or FUMP. It is evident therefore that the enzymes responsible for these reactions should be studied in human material in an attempt to explain the relative resistance to 5-FU seen in 75-80% of colorectal malignancies.
Studies on cultured cells which have been selected for their resistance to 5-FU have shown decreased levels of the enzyme PRT. Similarly decreased levels of UK have been detected in cells which are resistant to fluorouridine (Heidelberger et al., 1983) .
There are little data at the present time on these anabolic enzymes in human colorectal tissue. Weber (1980) Previous studies have shown that levels of UK are also elevated in malignant colorectal tissue (Weber, 1982) although the actual level may vary enormously (Otal-Brun & Webb, 1979 and Ahmed et al., 1982) . It is interesting to note that in 7 of our cases the level of UK in tumour tissue was either equivalent or less than the corresponding normal tissue. As with the results for PRT we were unable This study has demonstrated not only that the three enzymes responsible for conversion of 5-FU to 5-FUMP are present in malignant colorectal tissue but that in many cases the levels are increased over those found in corresponding paired non-malignant epithelium. It seems unlikely, therefore, that the diappointing clinical response to 5-FU in the majority of patients with colorectal malignancies is due to a deficiency in one of these vital anabolic enzymes. However, prior to investigating other parts of the metabolic pathway further work is needed, both on the specific kinetic constants of the enzymes and on the levels of substrates present in normal and malignant cells.
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